PIPELINE
Creating Transformative Solutions for Patients
Superior Pharmacokinetics Profile
INR301 is a novel, next-generation anti-PD-L1 antibody designed to penetrate the blood-brain barrier with high brain bioavailability without diminishing the systemic exposure.
Brain PK profiles in AD mice
Plasma PK profiles in AD mice
Brain and plasma PK profiles of control antibody
and INR301 at various time points in AD mice.
Superior Efficacy Profile
Our multimodal approach, targeting the immune checkpoint in the AD brain, significantly reduces GFAP (a marker for reactive astrocytes), amyloid beta plaques, and phosphorylated tau proteins.
Biomarkers in the subiculum of AD mice at 1 month after single IV injection
Click for graph
Mode of Action
Increasing evidence suggests that immune dysregulation, stemming from chronic and imbalanced inflammatory responses in the brain, underlies the pathophysiology of Alzheimer's disease (AD). Reprogramming the immune crosstalk among astrocytes, microglia, and neurons through the PD-1/PD-L1 immune checkpoint presents a novel therapeutic approach. INR301 is a first-in-class BBB-penetrating anti-PD-L1 antibody, a new treatment paradigm for AD by restoring immune balance in the brain.
INR301 treatment
Click for immunostaining
Alzheimer's disease
Click for immunostaining
INR301 targets PD-L1+ reactive astrocyte in the brain of AD mice
PD-1 and PD-L1 interaction in the brain of AD mice
INR301 treatment
Click for immunostaining
Alzheimer's disease
Click for immunostaining
INR301 targets PD-L1+ reactive astrocyte in the brain of AD mice
PD-1 and PD-L1 interaction in the brain of AD mice
Discovery
Pre-Clinical
Early Clinical
Late Clinical
Candidate
Target
Indication
INR303
Undisclosed
Neurodegeneration
INR302
Undisclosed
Alzheimer's
INR301
PD-L1
Alzheimer's
TRANSMAB® Platform
Candidate | Target | Indication | Discovery | Pre-Clinical | Early Clinical | Late Clinical |
---|---|---|---|---|---|---|
INR301 | PD-L1 | Alzheimer's | ||||
INR302 | Undisclosed | Alzheimer's | ||||
INR303 | Undisclosed | Neurodegeneration |